Pandemic Influenza Clinical Trial
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose
schedule in immunologically naïve adults against one vaccine formulation without adjuvant in
terms of tolerance and immunogenicity
Primary Objective:
To describe the safety profile and immunogenicity following each injection.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00971542 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
|
Phase 3 | |
| Completed |
NCT00976469 -
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
|
Phase 1/Phase 2 | |
| Completed |
NCT00535665 -
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
|
Phase 2 | |
| Completed |
NCT00950456 -
Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine
|
N/A | |
| Completed |
NCT00908687 -
A/H5N1/LT Dose Ranging Study
|
Phase 2 | |
| Completed |
NCT00783926 -
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
|
Phase 1 | |
| Completed |
NCT00519389 -
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06046092 -
H7HLAII DNA Influenza Vaccine
|
Phase 1 | |
| Completed |
NCT01640691 -
Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT01053143 -
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India
|
Phase 3 | |
| Completed |
NCT00660257 -
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
|
Phase 1 | |
| Completed |
NCT00970177 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
|
Phase 3 | |
| Completed |
NCT00971100 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
|
Phase 3 | |
| Completed |
NCT00971906 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
|
Phase 3 | |
| Completed |
NCT00959465 -
A/H1N1 Immunogenicity and Safety in Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT00532792 -
A/H5N1 Dose Ranging Study With Adjuvant Patch
|
Phase 1 | |
| Withdrawn |
NCT00640302 -
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza
|
N/A | |
| Withdrawn |
NCT00640874 -
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza
|
N/A | |
| Withdrawn |
NCT00640211 -
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B
|
N/A |